B. Joanne Power gives us a summary of the conference highlights from BioMalPar XV, including new strategies for vector control and new insights into the malaria parasite.
Browsing: Disease Area > Viral
In this interview we speak to Vincent Racaniello, Professor of Microbiology & Immunology, about his work on polio, picornaviruses and publicizing science through blogs and podcasts.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
A new study has implicated the cytokine interferon gamma as a major contributor of blood–brain barrier breakdown in central nervous system infections.
Researchers from the University of Texas at Austin have passed an experimental RSV vaccine through Phase I human clinical trial with promising results.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
Despite long-term antiretroviral therapy, cerebrospinal HIV reservoirs have been identified in individuals living with the virus and linked with a higher rate of cognitive defects.
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.